MA
SRRA

Minerva Advisors’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Minerva Advisors’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-797
Closed -$49K – 75
2017
Q3 		$49K Hold
797
– – 0.03% 73
2017
Q2 		$58K Hold
797
– – 0.03% 75
2017
Q1 		$58K Sell
797
-376
-32% -$21.9K 0.03% 73
2016
Q4 		$70K Sell
1,173
-1,685
-59% -$105K 0.04% 67
2016
Q3 		$208K Hold
2,858
– – 0.13% 64
2016
Q2 		$227K Buy
+2,858
New +$545K 0.15% 63

Other funds holding SRRA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Minerva Advisors's SRRA Position: Q4 2017 in Review

Minerva Advisors sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q4 2017, closing a stake of 797 shares — an estimated $49K sold.

Minerva Advisors first reported a position in SRRA in Q2 2016 and held it in 6 quarters. The position peaked at $227K in Q2 2016. 51 funds tracked by Wall St. Rank hold SRRA as of Q4 2017.

  • Minerva Advisors reported no remaining Sierra Oncology, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Minerva Advisors sold 797 Sierra Oncology, Inc. Common Stock shares in Q4 2017, an estimated $49K.
  • Minerva Advisors first reported a position in Sierra Oncology, Inc. Common Stock in Q2 2016 and held it in 6 quarters.
  • Minerva Advisors's Sierra Oncology, Inc. Common Stock position peaked at $227K in Q2 2016.
  • 51 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q4 2017.

Based on Minerva Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.